Viagra lost patent for the first time
Pfizer Canada-based company lost a legal battle aphrodisiac patent. The court considered that the application for a patent, Pfizer had not played fair play.
Supreme Court of Canada has overturned potency of Viagra patent
protection, and thus opened up the preparation of the corresponding free competition in the road of generic drugs. The court considered that Viagra manufactured by Pfizer had been too vague patent legality, so the exclusive right to manufacture in Canada is canceled.
The judgment was set unanimously by the Israeli company Teva Pharmaceutical petition strain and found that Pfizer had identified Viagra For the sole active ingredient and its mode of action as required by law.
The right of the patent system is based on reciprocity: the inventor receives a certain period to a new, useful product exclusive rights, provided that, in turn, explains his invention enough, so that society can benefit from the expiry of the patent for that information.
Pfizer did not tell that Viagra's only active ingredient is sildenafil, but listed a number of other substances that have been used in the treatment of men with erectile dysfunction.
- Applicants can not try to play games system in this way. Therefore, the patent is invalid, one of the seven judges announced the decision right.
Analysts do not believe in big effects
Teva has been trying to repeal the patent for Viagra in the past in the United States, Spain, Norway and New Zealand, but their decision has been reversed. Teva Canada both experienced the first two losses in the lower courts.
Viagra is Pfizer's one of the best-selling product of six. It is purchased with one and a half billion euros every year. The company does not trade secrecy, please Canada-markets monetary value.
Analysis of the company Morningstar, according to Canada's decision is unlikely to have great significance for Viagra
, the US capital market. Gabelli & Co. -analyysiyhtiössä, it is believed that even the decision to significantly benefit from Teva.